
Wednesday, July 24, 2024 11:09:12 AM
Volume: | - |
Day Range: | |
Bid: | |
Ask: | |
Last Trade Time: | |
Total Trades: |
Recent CATX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:29:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:28:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:27:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:25:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:22:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2025 09:18:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2025 01:00:16 PM
- Perspective Therapeutics to Present at Upcoming March Investor Conferences • GlobeNewswire Inc. • 02/26/2025 12:00:00 PM
- Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results • GlobeNewswire Inc. • 02/21/2025 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 04:37:42 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 03:26:05 PM
- Perspective Therapeutics to Participate in Upcoming February Investor Conferences • GlobeNewswire Inc. • 02/05/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2025 09:09:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2025 12:26:49 PM
- Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium • GlobeNewswire Inc. • 01/24/2025 12:00:00 PM
- Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 • GlobeNewswire Inc. • 01/22/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:36:16 PM
- Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/13/2025 01:00:00 PM
- Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2025 09:50:41 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2025 09:48:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2025 01:05:24 PM
- Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer • GlobeNewswire Inc. • 01/06/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 09:05:03 PM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM
$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market • NRXS • Mar 11, 2025 10:30 AM
UC Asset Acquired $3M Cannabis Property via Non-Cash Deal • UCASU • Mar 11, 2025 9:53 AM
1606 Corp. Signs LOI to Be Acquired by Private Group Seeking to Enter the Public Markets and Utilize AI Technologies for Potential Uplisting • CBDW • Mar 11, 2025 8:30 AM